10-Q: China Foods Holdings Reports Q3 Revenue Surge Amid Margin Squeeze

China Foods Holdings Ltd. reported a significant increase in revenue for the third quarter and nine months ended September 30, 2025, driven by healthcare product sales, but faced a substantial decline in gross profit margin and an increased working capital deficit.

Summary

• Revenue for the three months ended September 30, 2025, increased to $96,828 from $22,403 in the prior year period.
• Nine-month revenue surged to $239,083 from $50,020 year-over-year.
• Net loss for the three months decreased to $79,246 from $127,173.
• Net loss for the nine months decreased to $280,153 from $297,132.
• Gross profit margin for the nine months ended September 30, 2025, significantly decreased to 10% from 43% in the prior year, primarily due to higher product sourcing costs.
• The company reported a working capital deficit of $1,179,829 as of September 30, 2025.
• Disclosure controls and procedures were deemed not effective as of the end of the reporting period.

Sentiment

Score: 3

Explanation: While revenue growth is strong, the significant decline in gross profit margin, persistent net losses, increasing working capital deficit, and ineffective disclosure controls indicate substantial operational and financial challenges. The reliance on related party financing for going concern is a major concern.

Positives

• Significant revenue growth for both the three and nine months ended September 30, 2025, primarily driven by rising demand in the Chinese healthcare market and an expanded distribution network.
• Net loss decreased for both the three-month ($79,246 vs. $127,173) and nine-month ($280,153 vs. $297,132) periods compared to the prior year.
• Operating expenses decreased for both periods, contributing to the reduced net loss.
• Cash and cash equivalents increased to $76,861 as of September 30, 2025, from $39,192 at December 31, 2024.
• The company has legally binding agreements with its controlling shareholder to provide financial support for at least the next 12 months, mitigating immediate going concern risks.

Negatives

• Gross profit margin for the nine months ended September 30, 2025, significantly decreased to 10% from 43% in the prior year, primarily due to higher product sourcing costs.
• The company incurred a net loss of $280,153 for the nine months ended September 30, 2025.
• A substantial working capital deficit of $1,179,829 was reported as of September 30, 2025.
• Total stockholders' deficit increased to $1,148,732 as of September 30, 2025, from $850,807 at December 31, 2024.
• Net cash used in operating activities increased to $255,911 for the nine months ended September 30, 2025, from $201,678 in the prior year.
• Heavy reliance on advances from directors, a related company, and related parties for financing activities.
• Disclosure controls and procedures were evaluated as not effective.

Risks

• Liquidity Risk: The company has a significant working capital deficit and net losses, making it dependent on continued financial support from stockholders to meet obligations.
• Concentration Risk (Customers): Two customers accounted for 61% and 31% of the company's revenues for the nine months ended September 30, 2025, and a single customer accounted for 99% of revenues for the three months ended September 30, 2024, all located in the PRC.
• Concentration Risk (Vendors): Three vendors accounted for 61%, 13%, and 11% of purchases for the nine months ended September 30, 2025, all located in the PRC.
• Economic and Political Risk: Major operations in the PRC expose the company to the political, economic, and legal environments of China.
• Exchange Rate Risk: Fluctuations in HKD and RMB to US$ exchange rates can impact reported profits.
• Supply Chain and Pricing Risk: Recent trade tensions and high tariffs pose potential risks to the supply chain and pricing, though the company is implementing mitigation strategies.
• Internal Control Weaknesses: Disclosure controls and procedures were not effective, indicating potential risks in financial reporting accuracy and timeliness.

Future Outlook

Management believes that all statements expressing expectations and projections with respect to future matters are forward-looking statements. The company is actively monitoring trade tensions and high tariffs, implementing strategies such as supplier diversification, local sourcing, and logistics optimization to mitigate potential impacts. The company is committed to providing holistic, accessible, and customized wellness solutions.

Management Comments

• Management believes the existing stockholders will provide the additional cash to meet with the Company's obligations as they become due.
• The Company continued to operate and fulfill contractual obligations during the period and has received substantial customer payments and has ongoing signed contracts that are expected to result in revenue recognition in the near future, supporting the continuity of its business operations.
• Management has concluded that there is no substantial doubt about the Company's ability to continue as a going concern for at least 12 months from the date of issuance of these financial statements.
• The increase in revenue was primarily driven by rising demand in the Chinese healthcare market and the Company's expanded distribution network, which enabled higher sales volumes.
• The decrease in gross profit margin for the periods ended September 30, 2025, compared to the same periods in 2024, is primarily due to increased cost of revenue from sourcing products at higher costs, which offset the revenue growth driven by rising demand in the Chinese healthcare market.
• The decrease in net loss for the three and nine months ended September 30, 2025, was primarily attributed to the decrease in operating costs.
• Our President and Principal Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective.

Industry Context

The company operates in the health and wellness sector in China and Hong Kong, a market experiencing rising demand. Its diversification into high-end wine products was a response to the COVID-19 pandemic's impact on the healthcare industry. The company's strategy of customized science-based wellness consultation and services, along with e-commerce and social media distribution, aligns with broader trends in personalized health and digital sales channels. However, the significant decline in gross profit margin due to higher sourcing costs suggests challenges in managing supply chain economics within a competitive or evolving market.

Comparison to Industry Standards

• The company's gross profit margin of 10% for the nine months ended September 30, 2025, is significantly lower than the 43% reported in the prior year, indicating a substantial deterioration in profitability per unit of revenue. This margin is generally low for a health and wellness product company, which often see higher margins, especially for specialized products or services.
• The reliance on a few major customers (61% and 31% from two customers) and vendors (61%, 13%, 11% from three vendors) indicates a high concentration risk, which is generally considered less favorable than a diversified customer/vendor base in most industries.
• The persistent net losses and increasing stockholders' deficit, coupled with a significant working capital deficit, suggest the company is not yet achieving sustainable profitability or positive cash flow from operations, which is below the standard for mature, healthy businesses.
• The disclosure of 'not effective' disclosure controls and procedures is a significant governance and operational red flag, falling short of expected industry standards for public companies.

Corporate Governance

Related Party Transactions

• The company owed $449,202 to its director as of September 30, 2025 (up from $360,858 at December 31, 2024).
• The company owed $359,633 to a related company (sharing a common director) as of September 30, 2025 (up from $290,649 at December 31, 2024).
• The company owed $320,809 to another related party as of September 30, 2025 (up from $166,423 at December 31, 2024).
• These advances are unsecured, non-interest bearing, and due on demand.
• Net cash provided by financing activities for the nine months ended September 30, 2025, included $88,344 from directors, $68,984 from a related company, and $154,386 from related parties.

Stakeholder Impact

• Shareholders: Face significant dilution risk if future capital raises involve equity. The increasing stockholders' deficit and reliance on related party financing indicate a precarious financial position. Ineffective disclosure controls pose a risk to the reliability of reported financial information.
• Creditors: The company's significant working capital deficit and dependence on related party support for going concern raise concerns about its ability to meet obligations to other creditors.
• Employees: Continued net losses and liquidity challenges could impact job security or future growth opportunities.
• Customers/Suppliers: Concentration risks with major customers and vendors could lead to instability if relationships change or market conditions shift.

Next Steps

• Continue to monitor trade tensions and high tariffs, implementing strategies such as supplier diversification, local sourcing, and logistics optimization.
• Management will continue to rely on cash generated through financing from existing stockholders and private placements of securities.
• Implement clearer communication protocols, SEC compliance training, and increased frequency of manual control reviews to mitigate issues with disclosure controls.

Key Dates

Recommendation

Despite strong revenue growth, the company's financial health is deteriorating significantly. The gross profit margin has plummeted from 43% to 10% year-over-year for the nine-month period, indicating severe pressure on profitability. The working capital deficit has worsened, and the company continues to incur substantial net losses, increasing its total stockholders' deficit. Its going concern is entirely dependent on continued, unsecured, non-interest-bearing advances from related parties, which is an unsustainable long-term strategy. Furthermore, the disclosure that internal controls over financial reporting are 'not effective' is a major red flag for investors, signaling potential unreliability in financial reporting and significant governance issues. These factors collectively point to a highly distressed financial situation with substantial risks, making the stock a strong sell.

Keywords

Healthcare, Wellness, Supplements, Wine Products, China Market, SEC Filing, 10-Q, Financial Results, Revenue Growth, Gross Margin, Net Loss, Liquidity, Going Concern, Related Party Transactions, Internal Controls, Hong Kong, PRC